Artemis Medicare Services Ltd (ARTEMISMED) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company demonstrated steady growth momentum in the quarter, driven by strong performance in core specialties like cardiac sciences, oncology, and neurosciences, leading to a consolidated revenue increase of 13.8% year-over-year.
- A significant driver of performance was the international patient segment, which contributed approximately 32% of revenues, reinforcing the company's leadership in the medical value travel sector.
- Operational efficiency and an enhanced case mix at the flagship Gurugram facility resulted in improved profitability, with the consolidated EBITDA margin expanding to 21.2% from 20.6% in the same quarter of the previous year.
- Strategic capacity expansion is a key theme, with the addition of five new operation theatres and expanded units in nephrology and bone marrow transplant, which are expected to contribute meaningfully in the second half of the year.
- The company is advancing its long-term growth strategy with key projects on track, including a 300-bed facility in Raipur set for commissioning by the end of FY26 and a major 650-bed hospital planned for South Delhi.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.